Why it's different
Orforglipron is a GLP-1 pill that doesn't need an empty stomach or the 30-minute wait that oral semaglutide requires.
What the trials show so far
| Study | Result |
|---|---|
| ATTAIN-1 (2025) | Average weight loss of about 12.4% at 72 weeks on the highest dose (36 mg) vs about 0.9% on placebo, in adults with obesity without diabetes. |
| ACHIEVE-1 (2025) | In type 2 diabetes, A1C fell about 1.3 to 1.6 points at 40 weeks, with weight loss up to about 7.9%. |
Approved options today
Alongside it, compare approved medicines: Zepbound vs Wegovy, the Wegovy pill and the full medicine list.
Foundayo carries the same boxed warning about thyroid C-cell tumors as other GLP-1 medicines. This page will get a full label summary once we have reviewed the prescribing information.
Explainer · 0:23
Read the transcript
- After you eat, your gut releases a hormone called GLP-1. GLP-1 medicines copy it, but last much longer in the body.
- It slows how fast your stomach empties, so you feel full sooner and stay full for longer.
- It also acts on appetite centers in the brain, which quiets hunger and constant thoughts about food.
- When blood sugar is high, it helps the pancreas release insulin. Tirzepatide also acts on a second gut hormone, GIP.
Common questions
Is Orforglipron FDA-approved?
FDA-approved on April 1, 2026 as Foundayo, a once-daily pill for chronic weight management in adults with obesity, or overweight with a weight-related condition. Check the label for full details.
Who makes Orforglipron?
Eli Lilly.
Sources
Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error